ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Ossia M EichhoffCorinne I StoffelJan KäslerLuzia BrikerPatrick TurkoGergely KarsaiNina ZilaVerena PaulitschkePhil Fang ChengAlexander LeitnerAndrea BileckNicola ZamboniAnja IrmischZsolt BalazsAizhan TastanovaSusana PascoalPål JohannsenRebekka WegmannJulien MenaAlaa OthmanVasanthi S ViswanathanJudith WenzinaAndrea AloiaAnnalisa SaltariAndreas Dzungnull nullMichael KrauthammerStuart L SchreiberThorsten HornemannMartin DistelBerend SnijderReinhard DummerMitchell Paul LevesquePublished in: Cancer research (2023)
Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.